基于肝硬度的策略可预测丙肝肝硬化患者(伴或不伴HIV合并感染)在持续病毒学应答后无静脉曲张出血
评估HEPAVIR、扩展Baveno VI和HIV肝硬化标准在SVR时预测首次静脉曲张出血(VB)的诊断准确性,发现三种标准阴性预测值均极高(99.5%-100%),可安全减少不必要的内镜筛查。
要点
- HEPAVIR、扩展Baveno VI和HIV肝硬化标准在SVR后预测首次VB的阴性预测值分别为99.5%、100%和100%。
- 三种标准分别可减少45%、39%和44%的上消化道内镜筛查。
- HIV合并感染不影响三种标准的预测性能,HIV肝硬化标准在避免内镜方面最优且无遗漏VB。
核心结论
- SVR后基于肝硬度的预测策略能准确识别HCV肝硬化患者(无论是否合并HIV)中静脉曲张出血低风险者。
- 使用HIV肝硬化标准可最大化减少上消化道内镜筛查且不遗漏静脉曲张出血事件。
研究设计与样本
- 纳入标准:直接抗病毒药物治疗后获得SVR;治疗前肝硬度≥9.5 kPa;SVR时点肝硬度≥14 kPa。
主要发现
- SVR后7例(1.6%)患者发生首次静脉曲张出血。
- 在无既往VB史的患者中,HEPAVIR、扩展Baveno VI和HIV肝硬化标准的阴性预测值分别为99.5%(95%CI 97.1%-100%)、100%(95%CI 97.8%-100%)和100%(95%CI 98%-100%)。
- 三种标准分别减少45%、39%和44%的上消化道内镜筛查。
- HIV合并感染与否,三种标准的性能相似。
关键数值与推荐
- HEPAVIR标准:阴性预测值99.5%(95%CI 97.1%-100%),减少45%内镜。
- 扩展Baveno VI标准:阴性预测值100%(95%CI 97.8%-100%),减少39%内镜。
- HIV肝硬化标准:阴性预测值100%(95%CI 98%-100%),减少44%内镜。
临床怎么用
- 对HCV肝硬化患者获得SVR后,可依据肝硬度-based标准(如HIV肝硬化标准)识别静脉曲张出血低风险者,安全避免不必要的上消化道内镜筛查。
- 合并HIV感染不影响标准性能,HIV/HCV合并感染者同样适用。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the setting of hepatitis C virus (HCV) active infection, liver stiffness (LS)-based strategies identify patients with low risk of developing esophageal variceal bleeding (VB) episodes, in whom unnecessary upper esophagogastroduodenoscopy (UGE) screening can be safely avoided. However, after sustained virological response (SVR), data on the accuracy of the criteria predicting this outcome in HCV-infected patients with cirrhosis, with or without human immunodeficiency virus (HIV) coinfection, are very limited. METHODS: This was a multicenter prospective cohort study, where HCV-monoinfected patients and HIV/HCV-coinfected individuals were included if they had (1) SVR with direct-acting antiviral-based therapy; (2) LS ≥9.5 kPa previous to treatment; and (3) LS measurement at the SVR time-point ≥14 kPa. Diagnostic accuracy of HEPAVIR, expanded Baveno VI, and HIV cirrhosis criteria, at the time of SVR, was evaluated. Missed VB episodes, negative predictive values (NPVs), and number of spared UGEs were specifically assessed. RESULTS: Four hundred thirty-five patients were included, 284 (65%) coinfected with HIV. Seven (1.6%) patients developed a first episode of VB after SVR. In patients without a previous VB episode, HEPAVIR, expanded Baveno VI and HIV cirrhosis criteria achieved NPV for first VB episode after SVR of 99.5% (95% confidence interval [CI], 97.1%-100%), 100% (95% CI 97.8%-100%), and 100% (95% CI 98%-100%) while sparing 45%, 39%, and 44% of UGEs, respectively. When considering HIV coinfection, the performance of the 3 criteria was similar, both in HCV-monoinfected and HIV/HCV-coinfected individuals. CONCLUSIONS: After SVR, predictive LS-based strategies accurately identify HCV-infected patients, HIV coinfected or not, with low risk of developing VB during follow-up. In these specific patients, using HIV cirrhosis criteria maximize the number of spared UGEs while missing no VB episode.
引用
- Corma-Gómez A, Macías J, Morano L, et al. Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response. Clin Infect Dis. 2021. PMID: 33211801. doi:10.1093/cid/ciaa1726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。